Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
LENALEX, LENALIDE, LENALIDOMIDE JUNO (Juno Pharmaceuticals Pty Ltd)
Product name
LENALEX, LENALIDE, LENALIDOMIDE JUNO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
149 (255 working days)
Active ingredients
lenalidomide
Registration type
New generic medicine
Indication
Multiple Myeloma (MM)
LENALEX, LENALIDE, LENALIDOMIDE JUNO (capsule) is indicated for treatment of multiple myeloma.
Myelodysplastic Syndromes (MDS)
LENALEX, LENALIDE, LENALIDOMIDE JUNO is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Mantle Cell Lymphoma (MCL)
LENALEX, LENALIDE, LENALIDOMIDE JUNO is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.